Please assess the completion status of the following clinical trial:

Trial Title: Neural Substrates in Nicotine Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smokers who are between 18 and 65 years of age who self-report smoking at least 10 cigarettes (menthol and non-menthol) per day for at least the last 6 months.~* Healthy as determined by the Study Physician, based on a medical evaluation including medical history and physical examination, psychiatric evaluation, and liver function tests (LFTs and GGT enzyme levels).~* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.~* Women of childbearing potential must consent to use a medically accepted method of birth control while participating in the study (e.g., condoms and spermicide, oral contraceptive, Depo-provera injection, contraceptive patch, tubal ligation) and have 3 months of regular menstrual cycles.~* Capable of providing a Carbon Monoxide (CO) breath test reading greater than 10 parts per million (ppm) at the medical screening visit.~Exclusion Criteria:~Smoking behavior~* Current enrollment or plans to enroll in another research or smoking cessation program in the next 3 months.~* Provide a CO reading less than or equal to 10ppm at the medical screening visit.~* Plans to use nicotine substitutes (gum, patch, lozenge, e-cigarette) while enrolled in the study.~Alcohol/Drug Exclusion:~* History (past 2 years) or current diagnosis of substance abuse and/or currently receiving treatment for substance abuse (alcohol, THC, cocaine, PCP, amphetamines, methamphetamines, MDMA/ecstasy, opiates, methadone, benzodiazepines, tricyclic antidepressants, and barbiturates).~* Current alcohol consumption that exceeds 21 standard drinks/week over the last 6 months.~* Positive urine drug screen (for substances listed previously) at the medical screening visit or either testing day.~* Breath Alcohol Concentration (BrAC) assessment greater than or equal to 0.01 at medical screening visit or either testing day.~Medication Exclusion Criteria:~Current use or recent discontinuation (within last 28 days) of any medication including the following:~* Any form of psychotropic medications including: Antipsychotics; Mood-stabilizers (e.g., lithium, valproic acid, carbamazepine/tegretol); Anti-depressants (tricyclics, SSRI's, MAOI's, non-selective MAOIs, Wellbutrin, St. John's Wort); Anti-anxiety/Anti-panic agents; Anti-obsessive agents; Prescription stimulants (e.g., Provigil, Ritalin); Diet Pills/Anorectics; Systemic Steroids; Daily medication for chronic pain (e.g., opiates) or muscle spasms; Daily use of over the counter stimulants in pill form (e.g., ephedrine)~* Anti-coagulants (e.g., Warfarin)~* Any heart medications (e.g., dobutamine, isoproterenol)~* Daily medication for asthma~* Parkinson's disease medications (e.g., levodopa, methyldopa, apomorphine)~* Sympathomimetic (e.g., albuterol, pseudoephedrine)~* Other smoking cessation medications (Wellbutrin/Zyban, Chantix/varenicline)~Medical Exclusion Criteria:~* Women who are pregnant, planning a pregnancy within the next 3 months, or lactating.~* History or current diagnosis of any Axis 1 disorder as identified by the MINI (Mini International Neuropsychiatric Interview) or self-report. For major depression, only a current diagnosis will be exclusionary.~* History or current diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD).~* Serious or unstable disease (e.g., cancer within the past 6 months \[except squamous cell carcinoma\], HIV, Parkinson's disease).~* History of epilepsy or a seizure disorder.~* History or current diagnosis (last 6-months) of abnormal rhythms and/or tachycardia (\>100 beats/minute); history or current diagnosis of COPD, cardiovascular disease (stroke, angina, coronary heart disease); heart attack in the last 6 months; uncontrolled hypertension (SBP\>150 or DBP\>90).~* History or current kidney and/or liver failure (including transplant), disease, or impairment (e.g., cirrhosis); history or current diagnosis of hepatitis (excluding hepatitis A); liver function tests more than 20% outside of the normal range; Gamma-glutamyl Transpepsidase (GGT) values greater than 20% outside the normal range.~* Allergy to the study medication, tolcapone (Tasmar).~* History of severe, uncontrolled muscle movements (e.g., uncontrolled jerking, twitching) or a certain severe muscle problem (rhabdomyolysis).~* Low or borderline intellectual functioning - determined by receiving a score of less than 90 on the Shipley Institute of Living Scale (SILS) which correlates with the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Estimated IQ Test (administered at the medical screening visit).~* Experience of dizziness or lightheadedness upon standing on a daily basis.~* Lifetime history of stroke.~fMRI Exclusion Criteria:~* Self-reported history of claustrophobia.~* Left-handedness.~* Color blindness.~* Any impairment preventing subjects from using response pad necessary for cognitive testing.~* Circumstances or conditions that may interfere with magnetic resonance imaging (MRI).~* Having a cochlear implant or wearing bilateral hearing aids.~* Self-reported history of head trauma (including being knocked unconscious for 3 minutes or greater and diagnosis of a concussion) or CNS tumor.~* Self-reported use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for MRI.~* History of gunshot wound.~* Weight greater than 300lbs. at medical screening or either testing day.~* Completion of cognitive testing in study #810493 or #811325 within the last 6 months.~Genetic Profile Exclusion Criteria:~* In order to balance the distribution of males and females, some participants who meet genotype and other eligibility criteria may not be enrolled in the study.~General Exclusion Criteria:~* Any medical condition or concomitant medication that could compromise subject safety or treatment, as determined by the Principal Investigator and/or Study Physician.~* Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Sugar Pill) (Type: PLACEBO_COMPARATOR): 11-day placebo-controlled medication period
- Tolcapone (Type: ACTIVE_COMPARATOR): 11-day phase, tapered dosing scheduled (Day 1: 100mg three times daily, Days 2-8: 200mg three times daily, Day 9: 200mg twice daily, Day 10: 200mg once daily, Day 11: 100mg once daily); oral dosing; medication is encapsulated by the University of Pennsylvania's Investigational Drug Service (IDS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete